Biomab is an innovative South African pharmaceutical business established by Eurolab in 2020 to bring originator pharmaceutical products, new chemical entities and new biologicals into the South African market. It is being made possible through strategic collaborations with international research and development agencies and pharmaceutical leaders.

Biomab was launched in 2020 through collaborations with Roche Pharma South Africa as well as the Center for Molecular Immunology in Cuba.
Further strategic partnerships are being pursued internationally which will see Biomab further entrench its standing in South Africa’s pharmaceutical sector. Other cancer medicines are also being explored for Biomab to offer on behalf of pharmaceutical companies.

Biomab’s strategic focus on innovation covers oncology and haematology medicines, as well as drugs used to treat debilitating long-term illnesses. Its purpose is to offer clinicians in South Africa and their patients a consistent pipeline of new therapies that improve patient safety, clinical outcomes and quality of life.

Biomab is a Eurolab-associated company, and its launch represents a further expansion of Eurolab’s strategic programme to improve access to cancer medicines, cut treatment costs, introduce new technologies and positively impact on cancer patient outcomes.